Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Hepatic OncologyOpen Access

Management of hepatocellular carcinoma prior to liver transplantation: latest developments

View Full Paper
Ask AI
Bookmark
Share

Authors

ARAntoine RobertUniversity of MichiganTHT HunoldUniversity of MichiganNPNeehar D. ParikhUniversity of Michigan

Discussion

Loading...

Member takes

Implication

Review reveals latest strategies for cancer control in patients with hepatocellular carcinoma, highlighting risks of therapies.

Key Points

  • Liver transplantation offers a 5-year survival rate exceeding 75% for hepatocellular carcinoma patients.
  • Patients often require locoregional therapies for cancer control while awaiting liver transplantation, despite risks.
  • Emerging data supports the use of immune checkpoint inhibitors, suggesting minimized rejection risk with careful management.
  • Allocation policies in the US restrict transplantation, indicating the need for effective bridging strategies.

Cite This Study

Robert et al. (2025) studied this question.

synapsesocial.com/papers/68c24317b210217d647a54cdhttps://doi.org/10.1080/20450923.2025.2549676
View Full Paper
Ask AI
Bookmark
Share